Risk Partners Life Sciences Roundtable 2025, thank you very much! 

Contact us

We congratulate Formycon AG on its successful uplisting to the Prime Standard of Deutsche Börse on November 12, 2024!

Welcome to the Prime Standard league: A new champion of life sciences and biosimilars has successfully made the step from the scale segment. We proudly congratulate Enno Spillner, Dr. Caroline Redeker, Daniel Marquard and the entire Formycon AG team on this great success and another important milestone on their way to becoming a global champion in the biosimilars sector!

Formycon AG specializes in the development of high-quality biosimilars, which represent a cost-effective alternative to original biopharmaceutical preparations. The company demonstrates its innovative strength particularly in the field of follow-on molecules and has successfully positioned itself as one of the leading suppliers of biosimilars. With its expertise in research and development, Formycon creates access to cutting-edge biopharmaceutical products that benefit patients worldwide and has now also attracted increasing interest from international investors. As a result, the company has now been listed in the Prime Standard.  

Risk Partners acted as Capital Markets Insurance Advisor in this transaction. Our team, consisting of Florian, Franziska and Björn, supported Formycon AG during the successful uplisting process from the Scale to the Prime Standard of the Frankfurt Stock Exchange on November 12, 2024.

We are particularly pleased to contribute our specialization and expertise as an insurance broker for life sciences and capital market transactions and to accompany a "neighbor" from the Planegg/Martinsried region.

Special thanks also go to our co-broker team at Dr. Ellwanger & Kramm GmbH & Co. KG, in particular Gregor Klingeler and Frieder Lang, for the trust they have placed in us and the great cooperation. If you have a similar project in mind and would appreciate our support, please do not hesitate to contact us about the added value of RP4brokers. 

Also read our other blog posts

Being Public

Prospectus liability insurance (POSI): Risk Partners publishes for you

Risk Partners on Going Public and the capital market blog on prospectus liability insurance In recent months, we have been able to share our expertise on prospectus liability insurance with a wide audience on two renowned platforms. Here is an overview: Kapitalmarkt.blog In the article "POSI insurance - The protective vest on the capital market", we explain why prospectus liability insurance is an indispensable tool for companies becoming active on the capital market. The article shows in a practical way how such insurance not only minimizes liability risks, but also strengthens investor confidence. GoingPublic Magazine In

Read more "
December 29, 2024
Cyber Security

"Digital Operational Resilience Act" (DORA regulation) from the perspective of venture capital and private equity funds

DORA regulation applies from January 2025. Significance for our private equity and venture capital clients The somewhat unwieldy name "Digital Operational Resilience Act" (DORA for short) has a very serious background and is fundamentally to be welcomed. After all, when we evaluate our claims in the context of cybercrime, PE and VC funds and their KVGs are those with the highest frequency of claims. It can be safely assumed that they are a "worthwhile target group" for cyber criminals based abroad.

Read more "
December 27, 2024
Life Sciences

Atrialis GmbH - experts in clinical trial insurance

Atrialis GmbH - experts in clinical trial insurance & Risk Partners will play in the same team in the future. LifeSciences - Leading risk concepts for leading science! Under this guiding principle, we have been able to advise innovative companies from the biotechnology, pharmaceutical and medical device sectors comprehensively on risk issues for many years and support them with suitable insurance solutions in all growth and study phases, from foundation to IPO and beyond (e.g. insuring a clinical trial). Together with my team at Risk Partners GmbH, we would like to continue our focus, our passion

Read more "
October 31, 2023
Life Sciences

Finance Day 2023

Growth capital for biotechnology: Yesterday, today, tomorrow! A few days ago, Jutta Zaglauer and Florian Eckstein from our team attended the Finance Day 2023 on the occasion of the 25th anniversary of biotechnology at the IZB - Innovation and Startup Center for Biotechnology. The event offered an exciting exchange and insights into current financing and capital market issues of biotechnology companies. As an experienced specialist insurance broker for the areas of life sciences, venture capital and IPOs, all three cornerstones of our "magic expertise triangle" were part of the exciting agenda. It was also interesting to discuss the importance of customized

Read more "
November 6, 2023
Management

How managers protect themselves from personal liability in the event of cyber incidents - #29Minutes by Control Risk & Risk Partners

How directors and officers protect themselves from personal liability in the event of cyber incidents - #29Minutes by Control Risk & Risk Partners Looking at our claims experience in the area of directors' and officers' liability in recent years, internal claims alleging inadequate cyber risk management and emergency management in the event of a cyber attack are unfortunately on the rise. In addition to special risk transfer solutions (cyber and CDI insurance), there are also very practical tips on how to react correctly if the worst comes to the worst. Following an exchange at a risk management conference in Q1 of this year

Read more "
November 8, 2023
Being Public

Earnings Call: one 0 too many - the Lyft CEO mistake

"Look, it was a bad mistake, and that's on me," CEO of LYFT Inc. The incident and possible insurance coverage. You may have also heard about the recent incident with LYFT. In the quarterly earnings report, LYFT originally stated that profit margins were up 500 basis points before correcting this to 50 basis points during the conference call. This clerical error caused the stock price to rise more than 60% in after-hours trading. This situation is exactly what investor relations teams that

Read more "
February 17, 2024